Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)

NCT02092532 ↗

Phase 4 Unknown 20 enrolled Southeast Retina Center, Georgia Regeneron Pharmaceuticals · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of intravitreal aflibercept injection (IAI) in patients with neovascular polypoidal choroidal vasculopathy.

Timeline

Start: 2014-03
Primary completion: 2015-03
Completion: 2016-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aflibercept	Protein / enzyme biologic	2 mg	Intravitreal

Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)

Summary

Timeline

Drugs

Indications